Achieve Life Sciences, Inc.
ACHV
$2.25
$0.0652.98%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 115.40% | 62.39% | 6.04% | 4.57% | 1.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 177.93% | 89.68% | 9.29% | -30.26% | -59.62% |
| Operating Income | -177.93% | -89.68% | -9.29% | 30.26% | 59.62% |
| Income Before Tax | -125.71% | -76.03% | -2.69% | 27.78% | 51.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -125.71% | -76.03% | -2.69% | 27.78% | 51.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -125.71% | -76.03% | -2.69% | 27.78% | 51.25% |
| EBIT | -177.93% | -89.68% | -9.29% | 30.26% | 59.62% |
| EBITDA | -180.25% | -90.50% | -9.34% | 30.46% | 59.91% |
| EPS Basic | -38.42% | -8.26% | 43.01% | 48.33% | 68.82% |
| Normalized Basic EPS | -47.64% | -5.23% | 43.36% | 48.77% | 71.83% |
| EPS Diluted | -38.42% | -8.26% | 43.01% | 48.33% | 68.88% |
| Normalized Diluted EPS | -47.64% | -5.23% | 43.36% | 48.77% | 71.83% |
| Average Basic Shares Outstanding | 63.05% | 62.61% | 80.16% | 39.79% | 56.36% |
| Average Diluted Shares Outstanding | 63.05% | 62.61% | 80.16% | 39.79% | 56.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
